← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Altay Therapeutics, Inc.
San Carlos, CA
$1,573,527
Total funding
5
Grants
Funding over time
peak $998.5K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$1,298,527 · 4
NSF$275,000 · 1
By mechanism
R43$1,298,527 · 4
—$275,000 · 1
Investigators at Altay Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer .$399,869
R43 · FY2022 · CA
The development of a STAT3 inhibitor for lung scleroderma$299,999
R43 · FY2024 · HL
Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD)$299,591
R43 · FY2022 · AR
The development of a transcriptional inhibitor for lung fibrosis.$299,068
R43 · FY2022 · HL
SBIR Phase I: Targeting the Root Cause of Ewing’s Sarcoma$275,000
· FY2023 · TIP